The overall ratings of 16 Pharmaceuticals stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Eli Lilly and Company (LLY) drops from a D to a F rating. Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. For more information, get Portfolio Grader’s complete analysis of LLY stock.

Prestige Brands Holdings, Inc. (PBH) experiences a ratings drop this week, going from last week’s C to a D. Prestige Brands Holdings, Inc. distributes over-the-counter healthcare and household cleaning products to retail stores in the United States, Canada and other international markets. For more information, get Portfolio Grader’s complete analysis of PBH stock.

GlaxoSmithKline plc Sponsored ADR (GSK) slips from a C to a D this week. GlaxoSmithKline plc Sponsored ADR is a research-based pharmaceutical company. The company also gets F’s in operating margin growth. For more information, get Portfolio Grader’s complete analysis of GSK stock.

Slipping from a D to a F rating, Mylan N.V. (MYL) takes a hit this week. Mylan N.V. is a global generic and specialty pharmaceuticals company. The company also gets F’s in operating margin growth, earnings growth, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of MYL stock.

This is a rough week for Pacira Pharmaceuticals, Inc. (PCRX). The company’s rating falls to F from the previous week’s D. Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company with focuses on the development, commercialization, and manufacturing of proprietary pharmaceutical products. The company also gets F’s in operating margin growth, earnings growth, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of PCRX stock.

Akorn, Inc.’s (AKRX) rating weakens this week, dropping to a D versus last week’s C. Akorn, Inc. engages in the manufacture and marketing of diagnostic and therapeutic ophthalmic pharmaceuticals products, niche hospital drugs, and injectable pharmaceuticals in the United States and internationally. For more information, get Portfolio Grader’s complete analysis of AKRX stock.

NeuroDerm Ltd. (NDRM) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in earnings momentum and return on equity. For more information, get Portfolio Grader’s complete analysis of NDRM stock.

This week, Intra-Cellular Therapies, Inc.’s (ITCI) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ITCI stock.

Nektar Therapeutics (NKTR) earns a D this week, moving down from last week’s grade of C. Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms. The company also gets F’s in sales growth. For more information, get Portfolio Grader’s complete analysis of NKTR stock.

Paratek Pharmaceuticals Inc (PRTK) declines this week from a D to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of PRTK stock.

Egalet Corporation (EGLT) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of EGLT stock.

This week, MediWound Ltd. (MDWD) drops from a D to a F rating. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of MDWD stock.

This week, Endocyte, Inc.’s (ECYT) rating worsens to a F from the company’s D rating a week ago. Endocyte, Inc. is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ECYT stock.

Slipping from a D to a F rating, Orexigen Therapeutics, Inc. (OREX) takes a hit this week. Orexigen Therapeutics, Inc. is focused on the development and commercialization of pharmaceutical products for the treatment of the central nervous system disorders with an initial focus on obesity. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of OREX stock.

This is a rough week for Bio-Path Holdings, Inc. (BPTH). The company’s rating falls to D from the previous week’s C. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of BPTH stock.

Marinus Pharmaceuticals Inc (MRNS) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of MRNS stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.